Testing blood markers to predict graft-versus-host disease
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial looks at two blood markers to predict the risk of acute graft-versus-host disease after an allogeneic stem cell transplant. If you qualify, your care team may use results to help anticipate and manage complications earlier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old
- You are currently admitted to the hospital
- You are receiving an allogeneic stem cell transplant (using stem cells from another person)
- The transplant is for treatment of a cancer (malignant disease)
- You are planned for this transplant as an inpatient
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
This Phase 1 study tests a new combination of medicines to prevent graft-versus-host disease (GVHD) after an allogeneic stem cell transplant. If it works well, it may lower the chance and severity of GVHD, which can affect skin, liver, and the gut.
This trial aims to develop a test using multiple biomarkers to predict how well patients will respond to treatment for acute graft-versus-host disease (GVHD) affecting the gut. It focuses on patients who are receiving an allogeneic stem cell transplant.
This study collects blood samples from patients who have survived at least 3 months after a stem cell transplant to identify markers that could predict chronic graft-versus-host disease (a condition where the transplanted cells attack the body). The goal is to develop a simple blood test that could help doctors catch and treat this complication earlier.
This trial checks how certain blood “biomarkers” change after you receive donor stem cells to rebuild your blood and immune system. The goal is to learn whether these markers can better predict your immune recovery after transplant.
This study is testing whether the timing of a stem cell infusion affects the chance of developing graft-versus-host disease (aGVHD), a common complication after transplant. It may help make transplants safer for people with blood cancers.
Hear when a new GVHD,Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.